Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 521 to 530 of 2443 total matches.

Cladribine (Mavenclad) for Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Jul 29, 2019  (Issue 1577)
(PML) compared to other MS treatments.1-3 Oral fingolimod (Gilenya), teriflunomide (Aubagio ...
The FDA has approved cladribine (Mavenclad – EMD Serono), a purine antimetabolite, for oral treatment of adults with relapsing forms of multiple sclerosis (MS), including relapsing-remitting disease and active secondary progressive MS (SPMS), who cannot tolerate or have had an inadequate response to other drugs indicated for treatment of MS. It is not recommended for use in patients with clinically isolated syndrome (CIS). IV cladribine, which is FDA-approved for treatment of hairy cell leukemia, has been used off-label for treatment of MS.
Med Lett Drugs Ther. 2019 Jul 29;61(1577):118-20 | Show Introduction Hide Introduction

Addendum: Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms

   
The Medical Letter on Drugs and Therapeutics • Jul 29, 2019  (Issue 1577)
Lett Drugs Ther 2019; 61:99), Table 1 should have included single-ingredient oral formulations ...
In our article on Bijuva, the oral fixed-dose combination of estradiol and progesterone (Med Lett Drugs Ther 2019; 61:99), Table 1 should have included single-ingredient oral formulations of estradiol and progesterone (see below). They will be added to the table as it appears online, along with medroxyprogesterone (Provera, and generics), another single-ingredient progestin available for use in women with an intact uterus who take systemic estrogen for menopausal symptoms. Taking generic estradiol and progesterone separately may be less convenient than taking Bijuva, but they cost less and...
Med Lett Drugs Ther. 2019 Jul 29;61(1577):120 | Show Introduction Hide Introduction

Drugs for Smoking Cessation

   
The Medical Letter on Drugs and Therapeutics • Jul 15, 2019  (Issue 1576)
in the US. Smoking cessation often requires both pharmacotherapy and behavioral support.1,2 NICOTINE REPLACEMENT ...
Smoking tobacco remains the primary preventable cause of death in the US. Smoking cessation often requires both pharmacotherapy and behavioral support.
Med Lett Drugs Ther. 2019 Jul 15;61(1576):105-10 | Show Introduction Hide Introduction

Benzhydrocodone/Acetaminophen (Apadaz) for Pain

   
The Medical Letter on Drugs and Therapeutics • Jul 15, 2019  (Issue 1576)
and acetaminophen or ibuprofen have been available for years and are the most abused opioid products in the US.1 ...
The FDA has approved Apadaz (KemPharm), a short-acting, fixed-dose combination of benzhydrocodone and acetaminophen, for short-term management (≤14 days) of acute pain severe enough to require an opioid and for which alternative treatment options are inadequate. Benzhydrocodone is a prodrug of hydrocodone. Fixed-dose combinations of short-acting hydrocodone and acetaminophen or ibuprofen have been available for years and are the most abused opioid products in the US. Apadaz was developed under the presumption that inclusion of the inactive prodrug would reduce the potential for...
Med Lett Drugs Ther. 2019 Jul 15;61(1576):110-2 | Show Introduction Hide Introduction

Expanded Table: Some Drugs for Smoking Cessation (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 15, 2019  (Issue 1576)
) Nicotine transdermal patch – generic NicoDerm CQ (GSK) 7, 14, 21 mg/24 hr patches 1 patch/day ...
View the Expanded Table: Some Drugs for Smoking Cessation
Med Lett Drugs Ther. 2019 Jul 15;61(1576):e112-4 | Show Introduction Hide Introduction

Tafenoquine (Arakoda; Krintafel) for Malaria

   
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019  (Issue 1575)
: ta fen’ oh kwin Arakoda: air’ uh koh’ duh Krintafel: krin tah fell Table 1. Primaquine ...
The oral antimalarial tafenoquine succinate, a long-acting analog of primaquine, has been approved by the FDA in 2 different strengths. Arakoda (100-mg tablets; Sixty Degrees) is indicated for the prophylaxis of malaria in adults. Krintafel (150-mg tablets; GSK) is indicated for the prevention of relapse (radical cure) of Plasmodium vivax malaria in patients ≥16 years old undergoing treatment for acute P. vivax infection.
Med Lett Drugs Ther. 2019 Jul 1;61(1575):101-4 | Show Introduction Hide Introduction

Colorectal Cancer Screening

   
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019  (Issue 1575)
(polyp) can prevent cancer from developing.1 WHO SHOULD BE SCREENED — Routine screening for colorectal ...
Most colorectal cancers arise from localized adenomatous polyps in a process that may take 10 years or more. Early detection and removal of a precancerous colonic lesion (polyp) can prevent cancer from developing.
Med Lett Drugs Ther. 2019 Jul 1;61(1575):97-9 | Show Introduction Hide Introduction

Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms

   
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019  (Issue 1575)
that are chemically similar to endogenous hormones such as estradiol and progesterone.1 FDA-approved formulations ...
The FDA has approved Bijuva (TherapeuticsMD), a fixed-dose combination of estradiol and progesterone, for oral treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause in women with an intact uterus. The manufacturer is marketing Bijuva as "the first and only FDA-approved combination of bio-identical estradiol and bio-identical progesterone in a single daily oral capsule".
Med Lett Drugs Ther. 2019 Jul 1;61(1575):99-101 | Show Introduction Hide Introduction

Expanded Table: Drugs for Malaria Prophylaxis (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019  (Issue 1575)
Pediatric 1 adult tab (250/100 mg) once/day 5-8 kg: ½ ped tab/day (1 ped tab is 62.5/25 mg) 9-10 kg ...
View the Expanded Table: Drugs for Prophylaxis of Malaria
Med Lett Drugs Ther. 2019 Jul 1;61(1575):e104-5 | Show Introduction Hide Introduction

Correction: Drugs for Chronic Heart Failure

   
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019  (Issue 1575)
Correction: Drugs for Chronic Heart Failure In our Drugs for Chronic Heart Failure article,1 our ...
In our Drugs for Chronic Heart Failure article,1 our description of the PARADIGM-HF trial comparing the combination of the ARB valsartan and the neprilysin inhibitor sacubitril (Entresto) with the ACE inhibitor enalapril for treatment of heart failure with reduced ejection fraction (HFrEF) characterized the dosage of enalapril as "suboptimal". Some readers have objected to that characterization.The FDA-approved dosage of enalapril for treatment of HFrEF is 2.5-20 mg twice daily. In PARADIGM-HF, the dosage was capped at 10 mg twice daily, a widely used dosage that has been shown to reduce...
Med Lett Drugs Ther. 2019 Jul 1;61(1575):104 | Show Introduction Hide Introduction